SCHEMBL1103312

SCHEMBL1103312

C1=Cc2ccccc2N(c2c3ccccc3c(N3c4ccccc4C=Cc4ccccc43)c3c2cnc2ccccc23)c2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.35
GPR3 P46089 1/20 0.35
PDPK1 O15530 1/20 0.35
GRM5 P41594 2/20 0.32
CDK4 P11802 1/20 0.32
CCND1 P24385 1/20 0.32
TLR7 Q9NYK1 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
TOP2A P11388 1/20 0.31
ADRB2 P07550 1/20 0.31
NCF1 P14598 1/20 0.31
GABRA1 P14867 1/20 0.30
GABRG2 P18507 1/20 0.30
GABRB3 P28472 1/20 0.30
GABRA5 P31644 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1103328 0.82 ADORA3 (0.38) KDM4EGPR3GRM5TLR7LMNA
SCHEMBL1103323 0.82 MPO (0.35) KDM4EGPR3PDPK1GRM5LMNA
SCHEMBL1103321 0.82 MPO (0.35) KDM4EGPR3PDPK1GRM5CDK4
SCHEMBL1103313 0.81 CDK4 (0.36) KDM4EGPR3PDPK1GRM5CDK4
SCHEMBL1103317 0.81 MAOA (0.35) KDM4EGPR3PDPK1HDAC6
SCHEMBL1103316 0.79 PDPK1 (0.35) KDM4EGPR3PDPK1CDK4CCND1
SCHEMBL1103326 0.79 TLR7 (0.35) KDM4EGPR3PDPK1GRM5TLR7
SCHEMBL1103334 0.77 KDM4E (0.31) KDM4EGPR3GRM5
SCHEMBL14174423 0.73 MAPK1 (0.38) LMNA
SCHEMBL1102734 0.72 P2RX4 (0.39) KDM4ELMNATP53TOP2AGABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-8153279-B2 Organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2012-04-10 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-02-11 US disclosed
EP-2147962-A1 Azaanthracene-derivatives and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100033083-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same ORMDL3, OCIAD2, OCIAD1 KDM4E 3367/4885GPR3 1503/4885PDPK1 3594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.